Overview
Double Blind Bio provides a subscription-based SaaS platform that uses AI to streamline clinical trial operations by connecting community research sites with sponsors. Its Debby AI agent automates site administrative workflows and offers AI-driven trial discovery, automated feasibility analysis, and sponsor outreach, all inside one platform with centralized site data and analytics. It differentiates itself by focusing on community sites and sponsor engagement, delivering an integrated workflow that combines discovery, feasibility, and outreach to reduce bottlenecks and speed up startup. Its goal is to accelerate the development of new medical treatments by increasing trial opportunities and speeding up the startup phase.
Work here?Claim your company
Simplify's take
What believers are saying
- October 15, 2026 product notes said summer usage grew quickly.
- July 2026 hiring post said Double Blind Bio onboarded 200 research sites.
- The company said it already landed a first pharma design partner and several sponsors.
What critics are saying
- Veeva eSource ships late 2026, compressing budgets for startup and workflow software.
- Crowded clinical-operations AI invites faster incumbents and point solutions to displace Debby.
- If site adoption stalls below 200-plus users, sponsor demand and fundraising weaken fast.
What makes Double Blind Bio unique
- Double Blind Bio embeds Debby inside site workflows, not just sponsor dashboards.
- Shruti Tibrewala and Dave Hughes combine life-sciences and enterprise software backgrounds.
- It targets community research sites first, building network effects for sponsors later.
Help us improve and share your feedback! Did you find this helpful?